$CYTH
Cyclo Therapeutics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000143774920018033 Filed on August 14, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $209.6K $273.1K
YoY Change -23.25% -21.84%
Cost Of Revenue $10.00K $16.31K
YoY Change -38.68% -69.82%
Gross Profit $200.0K $256.8K
YoY Change -22.11% -13.06%
Gross Profit Margin 95.42% 94.03%
Selling, General & Admin $680.0K $840.0K
YoY Change -19.05% 13.51%
% of Gross Profit 340.0% 327.12%
Research & Development $1.713M $786.8K
YoY Change 117.77% -6.82%
% of Gross Profit 856.72% 306.41%
Depreciation & Amortization $10.00K $0.00
YoY Change -100.0%
% of Gross Profit 5.0% 0.0%
Operating Expenses $1.713M $786.8K
YoY Change 117.77% -6.82%
Operating Profit -$2.202M -$1.370M
YoY Change 60.69% 5.83%
Interest Expense $10.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.192M -$1.368M
YoY Change 60.26% 6.11%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.192M -$1.368M
YoY Change 60.26% 6.11%
Net Earnings / Revenue -1046.02% -500.93%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.599M -$1.356M
COMMON SHARES
Basic Shares Outstanding 91.26M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.010M $6.610M
YoY Change -84.72% 329.22%
Cash & Equivalents $1.008M $6.608M
Short-Term Investments
Other Short-Term Assets $660.0K $28.49K
YoY Change 2216.68% -36.44%
Inventory $216.6K $397.6K
Prepaid Expenses
Receivables $161.2K $154.1K
Other Receivables $40.00K $40.00K
Total Short-Term Assets $2.088M $7.403M
YoY Change -71.8% 249.1%
LONG-TERM ASSETS
Property, Plant & Equipment $60.44K $16.93K
YoY Change 257.07% -24.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $178.2K
YoY Change
Total Long-Term Assets $174.2K $187.6K
YoY Change -7.13% 9.25%
TOTAL ASSETS
Total Short-Term Assets $2.088M $7.403M
Total Long-Term Assets $174.2K $187.6K
Total Assets $2.262M $7.591M
YoY Change -70.2% 231.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.980M $2.690M
YoY Change 47.96% 108.53%
Accrued Expenses $20.00K $10.00K
YoY Change 100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $60.88K
YoY Change
Total Short-Term Liabilities $4.057M $2.705M
YoY Change 50.0% 109.68%
LONG-TERM LIABILITIES
Long-Term Debt $97.65K $0.00
YoY Change
Other Long-Term Liabilities $30.00K $50.00K
YoY Change -40.0%
Total Long-Term Liabilities $125.1K $50.00K
YoY Change 150.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.057M $2.705M
Total Long-Term Liabilities $125.1K $50.00K
Total Liabilities $4.182M $2.750M
YoY Change 52.09% 113.18%
SHAREHOLDERS EQUITY
Retained Earnings -$29.95M -$20.86M
YoY Change 43.56% 35.15%
Common Stock $14.16K $12.05K
YoY Change 17.45% 38.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.920M $4.840M
YoY Change
Total Liabilities & Shareholders Equity $2.262M $7.591M
YoY Change -70.2% 231.13%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$2.192M -$1.368M
YoY Change 60.26% 6.11%
Depreciation, Depletion And Amortization $10.00K $0.00
YoY Change -100.0%
Cash From Operating Activities -$2.060M -$1.520M
YoY Change 35.53% 56.7%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $10.00K $10.00K
YoY Change 0.0% -50.0%
Cash From Investing Activities $10.00K $10.00K
YoY Change 0.0% -50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.130M 7.000M
YoY Change -69.57% 270.37%
NET CHANGE
Cash From Operating Activities -2.060M -1.520M
Cash From Investing Activities 10.00K 10.00K
Cash From Financing Activities 2.130M 7.000M
Net Change In Cash 80.00K 5.490M
YoY Change -98.54% 484.04%
FREE CASH FLOW
Cash From Operating Activities -$2.060M -$1.520M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$2.060M -$1.520M
YoY Change 35.53% 56.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3272177
CY2020Q2 ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
12947
CY2019Q2 ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
16309
ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
39380
ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
36859
CY2019Q1 ctdh Equity Impact Of Cash Received From Stock Subscription
EquityImpactOfCashReceivedFromStockSubscription
130062
CY2020Q2 ctdh Freight And Shipping
FreightAndShipping
1169
CY2019Q2 ctdh Freight And Shipping
FreightAndShipping
1016
ctdh Freight And Shipping
FreightAndShipping
3032
ctdh Freight And Shipping
FreightAndShipping
2450
ctdh Increase Decrease Prepaid Clinical Expenses
IncreaseDecreasePrepaidClinicalExpenses
-20485
ctdh Increase Decrease Prepaid Clinical Expenses
IncreaseDecreasePrepaidClinicalExpenses
178200
CY2016Q1 ctdh Mortgage Loans On Real Estate Monthly Payment
MortgageLoansOnRealEstateMonthlyPayment
3653
ctdh Number Of Major Customers
NumberOfMajorCustomers
3
ctdh Number Of Major Customers
NumberOfMajorCustomers
3
CY2020Q2 ctdh Operating Lease Right Of Usse Asset Amortization
OperatingLeaseRightOfUsseAssetAmortization
25507
CY2020Q2 ctdh Prepaid Expenses Current Excluding Prepaid Insurance
PrepaidExpensesCurrentExcludingPrepaidInsurance
591676
CY2019Q4 ctdh Prepaid Expenses Current Excluding Prepaid Insurance
PrepaidExpensesCurrentExcludingPrepaidInsurance
612161
ctdh Proceeds From Collection Of Stock Subscription
ProceedsFromCollectionOfStockSubscription
ctdh Proceeds From Collection Of Stock Subscription
ProceedsFromCollectionOfStockSubscription
130062
ctdh Proceeds From Sale Of Common Stock And Warrants Net Of Issue Costs
ProceedsFromSaleOfCommonStockAndWarrantsNetOfIssueCosts
1970363
ctdh Proceeds From Sale Of Common Stock And Warrants Net Of Issue Costs
ProceedsFromSaleOfCommonStockAndWarrantsNetOfIssueCosts
6989600
CY2020Q2 ctdh Repairs And Maintenance
RepairsAndMaintenance
1311
CY2019Q2 ctdh Repairs And Maintenance
RepairsAndMaintenance
1299
ctdh Repairs And Maintenance
RepairsAndMaintenance
3113
ctdh Repairs And Maintenance
RepairsAndMaintenance
2983
ctdh Sharebased Compensation Employees
SharebasedCompensationEmployees
4810
ctdh Sharebased Compensation Employees
SharebasedCompensationEmployees
13100
ctdh Sharebased Compensation Nonemployees
SharebasedCompensationNonemployees
9250
ctdh Sharebased Compensation Nonemployees
SharebasedCompensationNonemployees
54830
ctdh Working Capital
WorkingCapital
1969000
CY2016Q1 srt Mortgage Loans On Real Estate Face Amount Of Mortgages
MortgageLoansOnRealEstateFaceAmountOfMortgages
265000
CY2016Q1 srt Mortgage Loans On Real Estate Interest Rate
MortgageLoansOnRealEstateInterestRate
0.0425
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3979395
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3124735
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
161233
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
143429
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
28012423
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26044060
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
955928
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
525510
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6840
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14060
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
36540
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67930
CY2020Q2 us-gaap Assets
Assets
2262301
CY2019Q4 us-gaap Assets
Assets
4113228
CY2020Q2 us-gaap Assets Current
AssetsCurrent
2088085
CY2019Q4 us-gaap Assets Current
AssetsCurrent
3958069
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
60383
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1008355
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2783719
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2783719
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2217412
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1008355
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6607613
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1775364
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4390201
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
141671462
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
121564990
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
141671462
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
121564990
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
14155
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
12155
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
2411497
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
1643379
us-gaap Costs And Expenses
CostsAndExpenses
5379271
us-gaap Costs And Expenses
CostsAndExpenses
3771995
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4826384
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4057242
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3141120
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1272
us-gaap Depreciation
Depreciation
6236
us-gaap Depreciation
Depreciation
2969
CY2020Q2 us-gaap Depreciation Nonproduction
DepreciationNonproduction
3118
CY2019Q2 us-gaap Depreciation Nonproduction
DepreciationNonproduction
1485
us-gaap Depreciation Nonproduction
DepreciationNonproduction
6236
us-gaap Depreciation Nonproduction
DepreciationNonproduction
2969
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2192392
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1368011
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2262301
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4113228
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
840600
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
697370
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17804
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
74066
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-26021
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-18947
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-412
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-864
us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
-65918
us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
10304
us-gaap Interest Paid Net
InterestPaidNet
us-gaap Interest Paid Net
InterestPaidNet
CY2020Q2 us-gaap Inventory Net
InventoryNet
216609
CY2019Q4 us-gaap Inventory Net
InventoryNet
242630
CY2020Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
52922
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
52922
CY2020Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
9511
CY2019Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2273
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
17559
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
5897
CY2020Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
125098
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-7533000
us-gaap Net Income Loss
NetIncomeLoss
-3272177
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2633992
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
36126
CY2020Q2 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
71264
CY2019Q4 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
90596
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
60879
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
97645
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2128887
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7119662
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33795
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17206
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3870456
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2746667
us-gaap Net Income Loss
NetIncomeLoss
-4826384
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2192392
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1904166
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1368011
CY2020Q2 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
21367
CY2019Q2 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
31611
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
28716
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
64696
CY2020Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
39061
CY2019Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
39061
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2201903
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1370284
us-gaap Operating Income Loss
OperatingIncomeLoss
-4843943
us-gaap Operating Income Loss
OperatingIncomeLoss
-3278074
us-gaap Operating Lease Expense
OperatingLeaseExpense
8929
us-gaap Operating Lease Expense
OperatingLeaseExpense
11376
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16968
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16385
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27453
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36126
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
42515
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
51017
CY2020Q2 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
79823
CY2019Q2 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
247495
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
258185
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
350137
us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-19332
us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-18530
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
53127
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1324
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Prepaid Insurance
PrepaidInsurance
71151
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
137069
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
158524
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
CY2016Q1 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
10000
CY2020Q2 us-gaap Professional Fees
ProfessionalFees
143427
CY2019Q2 us-gaap Professional Fees
ProfessionalFees
246276
us-gaap Professional Fees
ProfessionalFees
362963
us-gaap Professional Fees
ProfessionalFees
461251
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60437
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13546
CY2020Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1272
CY2019Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3773041
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2129574
us-gaap Salaries And Wages
SalariesAndWages
721076
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1713435
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
786811
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29946617
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25120233
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
209594
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
273095
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
535328
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
493921
CY2020Q2 us-gaap Salaries And Wages
SalariesAndWages
433628
CY2019Q2 us-gaap Salaries And Wages
SalariesAndWages
311077
us-gaap Salaries And Wages
SalariesAndWages
903333
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1970363
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6989600
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-1920039
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
935982
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1698010
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
992524
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-781580
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
4840009
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(r) USE OF ESTIMATES&#x2013;&#x2013;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the consolidated financial statements and accompanying notes.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company's most significant estimate relates to inventory obsolescence. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates.</div></div></div></div></div></div></div></div></div></div>
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
136676101
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
101013435
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
129120546
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
95886380

Files In Submission

Name View Source Status
0001437749-20-018033-index-headers.html Edgar Link pending
0001437749-20-018033-index.html Edgar Link pending
0001437749-20-018033.txt Edgar Link pending
0001437749-20-018033-xbrl.zip Edgar Link pending
ctdh-20200630.xml Edgar Link completed
ctdh-20200630.xsd Edgar Link pending
ctdh-20200630_cal.xml Edgar Link unprocessable
ctdh-20200630_def.xml Edgar Link unprocessable
ctdh-20200630_lab.xml Edgar Link unprocessable
ctdh-20200630_pre.xml Edgar Link unprocessable
ctdh20200811_10q.htm Edgar Link pending
ex_198977.htm Edgar Link pending
ex_198978.htm Edgar Link pending
ex_198979.htm Edgar Link pending
ex_198980.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending